iShares Biotechnology ETF (NQ:IBB)

207.74 -1.80 (-0.86%)

Official Closing Price Updated: 4:15 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗

February 17, 2026

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗

February 17, 2026

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗

February 10, 2026

Via Stocktwits

HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗

February 09, 2026

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

Via Stocktwits

Why Is ALVO Stock Rising Pre-Market Today? ↗

February 05, 2026

The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.

Via Stocktwits

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗

January 16, 2026

Via Stocktwits

IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗

January 14, 2026

Via Stocktwits

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗

January 30, 2026

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.

Via Stocktwits

Why Did SER Stock Surge Over 70% In Pre-Market Today? ↗

January 29, 2026

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

Via Stocktwits

This Wealth Manager Just Dumped Its Entire $3.5 Million Stake in the iShares Biotech ETF ↗

January 27, 2026

The iShares Biotechnology ETF tracks U.S. biotech firms, offering exposure to companies advancing research, development, and innovation.

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

Why Did NRXP Stock Surge 21% Pre-Market Today? ↗

January 14, 2026

Via Stocktwits

IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients ↗

January 13, 2026

Via Stocktwits

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Via The Motley Fool

Topics ETFs Intellectual Property World Trade

The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare

January 23, 2026

The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock ↗

December 29, 2025

Via Stocktwits

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗

January 20, 2026

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

Via Stocktwits

Why This Fund Cashed Out of a $3.6 Million Biotech ETF Bet ↗

December 26, 2025

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? ↗

December 11, 2025

Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.

Via Stocktwits

Topics Artificial Intelligence Stocks

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗

December 01, 2025

Via MarketBeat

Clean Energy’s Second Wind: What iShares Global Clean Energy ETF Tells Us Now ↗

November 11, 2025

Clean Energy’s Second Wind: What iShares Global Clean Energy ETF Tells Us Now

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals ↗

November 03, 2025

Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals

Via The Motley Fool

Topics ETFs Regulatory Compliance

Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? ↗

November 03, 2025

Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025.

Via Benzinga

Topics ETFs

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗

October 27, 2025

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.

Via Benzinga

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗

October 15, 2025

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.

Via Benzinga

Enpro Moves To Boost Profits With $280 Million Acquisition Push ↗

October 13, 2025

Enpro Inc. (NYSE: NPO) acquiring AlpHa Measurement Solutions and Overlook Industries for $280 million in cash.

Via Benzinga

Financial Markets Signal Near 100% Probability of Fed Rate Cut: What it Means for the Economy and Investors

October 09, 2025

The financial markets are currently flashing a near 100% probability of a Federal Reserve interest rate cut at the upcoming October 28-29 Federal Open Market Committee (FOMC) meeting. This overwhelming...

Via MarketMinute

Topics Bonds Credit Cards Economy

Destiny Wealth Sells $8.1 Million in IBB Shares — Here’s Why Biotech Stocks Are Lagging ↗

October 07, 2025

Via The Motley Fool

Topics Artificial Intelligence ETFs Regulatory Compliance

How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline ↗

October 07, 2025

Trump's comments on health-care negotiations with Democrats can put ETFs like XLV, IHF, and XHS back on investors' radar as Washington's shutdown drags on.

Via Benzinga

Topics ETFs Government

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.